Three Lactobacillus strains (LOCK 0900, LOCK 0908, LOCK 0919) out of twenty-four isolates were selected according to their antagonistic activity against pathogenic bacteria, resistance to low pH and milieu of bile salts. Intragastric administration of a mixture of these strains to Balb/c mice affected cytokine T(H)1-T(H)2 balance toward nonallergic T(H)1 response. Spleen cells, isolated from lactobacilli-treated mice and re-stimulated in vitro with the mixture of heat-inactivated tested strains, produced significantly higher amounts of anti-allergic tumor necrosis factor- and interferon-gamma than control animals whereas the level of pro-allergic interleukin-5 was significantly lower. Lactobacillus cells did not translocate through the intestinal barrier into blood, liver and spleen; a few Lactobacillus cells found in mesenteric lymph nodes could create antigenic reservoir activating the immune system. The mixture of Lactobacillus LOCK 0900, LOCK 0908 and LOCK 0919 strains represents a probiotic bacterial preparation with possible use in prophylaxis and/or therapy of allergic diseases.

• MeSH
• Anti-Bacterial Agents pharmacology   MeSH
• Antibiosis MeSH
• Bacterial Translocation MeSH
• Stress, Physiological MeSH
• Interferon-gamma metabolism   MeSH
• Interleukin-5 metabolism   MeSH
• Liver microbiology   MeSH
• Blood microbiology   MeSH
• Cells, Cultured MeSH
• Acids pharmacology   MeSH
• Lactobacillus drug effects   physiology   MeSH
• Leukocytes, Mononuclear immunology   MeSH
• Mice, Inbred BALB C MeSH
• Mice MeSH
• Probiotics administration & dosage   pharmacology   MeSH
• Spleen immunology   microbiology   MeSH
• Tumor Necrosis Factor-alpha metabolism   MeSH
• Bile Acids and Salts pharmacology   MeSH
• Animals MeSH
• Check Tag
• Mice MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Anti-Bacterial Agents MeSH
• Interferon-gamma MeSH
• Interleukin-5 MeSH
• Acids MeSH
• Tumor Necrosis Factor-alpha MeSH
• Bile Acids and Salts MeSH

Our study examined whether repeated preventive oral administration of live probiotic bacterial strains Escherichia coli O83:K24:H31 (Ec O83), Escherichia coli Nissle 1917 O6:K5:H1 (Ec Nis) and Lactobacillus casei DN 114001 (Lc) can protect mice against dextran sodium sulfate (DSS)-induced colitis. A significant decrease in average symptom score was observed in Ec O83-, Ec Nis- and Lc-pretreated group (p < 0.05). Significant differences in body mass loss between Lc pretreated mice with DSS-induced colitis were found when compared with nontreated mice (p < 0.05). PBS pretreated mice had a significantly shorter colon than Ec O83-, Ec Nis- and Lc-pretreated mice (p < 0.05). Administration of Lc significantly decreased the severity of DSS induced histological marks of inflammation (p < 0.05). A significant difference (p < 0.05) was also found in specific IgA level against given probiotic in enteral fluid between colitic mice and healthy mice pretreated with Ec 083 and Ec Nis.

• MeSH
• Administration, Oral MeSH
• Escherichia coli MeSH
• Histocytochemistry MeSH
• Immunoglobulin A analysis   MeSH
• Colon microbiology   MeSH
• Lacticaseibacillus casei MeSH
• Disease Models, Animal MeSH
• Mice, Inbred BALB C MeSH
• Mice MeSH
• Probiotics pharmacology   MeSH
• Dextran Sulfate adverse effects   MeSH
• Intestinal Mucosa immunology   pathology   MeSH
• Colitis, Ulcerative chemically induced   immunology   prevention & control   MeSH
• Animals MeSH
• Check Tag
• Mice MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Immunoglobulin A MeSH
• Dextran Sulfate MeSH

The current incidence of Escherichia coli strains in healthy humans capable of producing the inhibitory exoproducts, such as temperate bacteriophages, corpuscular or HMW (high-molar mass) and proteinaceous or LMW (low-molar mass) colicins and siderophores was determined. Fifty-three E. coli strains were collected from the colons of 53 healthy human volunteers in Brno (Czechia) and tested for spontaneous and induced production of inhibitory exoproducts in a cross-test against each other. Of the strains tested, 37.7% produced bacteriophages, 41.5% produced from one to several LMW colicins, 11.3% formed HMW colicins and 15.1% (eight strains) produced exocellular siderophores different from enterochelin. Of these, seven strains formed aerobactin and one strain formed an untyped siderophore. E. coli strains differ greatly in the incidence of colicinogeny and lysogeny from its closest systemic relatives in the genus Escherichia and therefore should not be regarded as a model bacterium in this respect.

• MeSH
• Antibiosis physiology   MeSH
• Bacteriophages metabolism   MeSH
• Escherichia coli metabolism   MeSH
• Feces microbiology   MeSH
• Colicins metabolism   pharmacology   MeSH
• Colon microbiology   MeSH
• Humans MeSH
• Lysogeny physiology   MeSH
• Siderophores metabolism   pharmacology   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Colicins MeSH
• Siderophores MeSH

Concentrated extracts of MRS (De Man-Rogosa-Sharpe) media in which probiotic bacterium Enterococcus faecium strain M-74 was grown exerted different antimutagenic activity against ofloxacin-, N-methyl, N'-nitro-N-nitrosoguanidine- and sodium 5-nitro-2-furylacrylate-induced mutagenicity in Salmonella typhimurium assay depending on the presence (+Se) or absence of disodium selenite pentahydrate (-Se). The antimutagenicity of MRS(+Se) extract was higher than that of MRS(-Se) extract. Selenium enhanced also the antimutagenic effect of both live and killed cells of E. faecium M-74, respectively. The live bacteria decreased the mutagenicity of selected substances more than killed cells. Synergic activity of selenium with the bacterium was also manifested.

• MeSH
• Antimutagenic Agents pharmacology   MeSH
• Enterococcus faecium metabolism   physiology   MeSH
• Mutagenesis drug effects   MeSH
• Mutagens toxicity   MeSH
• Probiotics pharmacology   MeSH
• Salmonella typhimurium drug effects   genetics   MeSH
• Selenium pharmacology   MeSH
• Drug Synergism MeSH
• Mutagenicity Tests MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Antimutagenic Agents MeSH
• Mutagens MeSH
• Selenium MeSH